GlassScriptPhysician profile
Tracey A Hoffman
NPI 1306148671
$19,195.84
in general payments reported to CMS, 2019-2025
62 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,509 · 2022: $7,662 · 2023: $1,364 · 2024: $1,660 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,925 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $7,418.95 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $916.74 | 2021-2025 | Tagrisso, Imfinzi, Enhertu |
| Amgen INC. | $877.40 | 2021-2023 | Lumakras, Kyprolis, Xgeva |
| Incyte Corporation | $758.90 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $674.72 | 2021-2025 | Opdivo, Opdualag |
| Seagen INC. | $647.23 | 2021-2023 | Padcev, Tukysa |
| Merck Sharp & Dohme LLC | $560.96 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $547.29 | 2021-2025 | |
| Janssen Biotech, INC. | $495.88 | 2021-2024 | Erleada |
| Rigel Pharmaceuticals, INC. | $431.04 | 2021-2024 | Rezlidhia, Tavalisse |
| Pfizer INC. | $415.03 | 2021-2024 | |
| Genzyme Corporation | $347.53 | 2021-2022 | |
| Coherus Oncology, INC. | $342.95 | 2021-2023 | |
| Gilead Sciences, INC. | $342.74 | 2022-2024 | Trodelvy |
| Lilly USA, LLC | $271.99 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.